[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 15, Issue 2 (Spring 2024) ::
Caspian J Intern Med 2024, 15(2): 318-327 Back to browse issues page
Deaddicta® for maintenance treatment of Opioid-dependence: A six-month follow-up
Abdolali Moosavyzadeh , Farzaneh Ghaffari , Mohammad Bagher Mohammad Bagher Saberi zafarghandi , Majid Talafi Noghani , Hossein Hassanpour , Fatemeh Emadi , Fatemeh Alijaniha , Zahra Bahaeddin , Leila Nasiri , Razieh Jafari Hajati , Mohsen Naseri
Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran , naseri@shahed.ac.ir
Abstract:   (326 Views)
Background: Opioid dependence, is one of the world's most critical health problems. Deaddicta is a herbal product considered an effective treatment for opioid addiction. Deaddicta's efficacy in the maintenance treatment of patients with opioid use disorder has recently been demonstrated through a double-blind randomized controlled trial (RCT). This study aimed to evaluate the permanence of Deaddicta's efficacy six months after the end of the maintenance treatment for opioid dependence.
Methods: This study was performed following the previous RCT on the maintenance treatment of opioid addicts. Out of 41 participants who completed the study for three months in the previous research, 15 from the intervention group (Deaddicta capsules, 1500 mg/day) returned for follow-up. They all previously fulfilled the DSM-IV criteria for addiction, were aged 18 to 65, and had discontinued Deaddicta for six months. The outcome measures included addiction severity, depression and anxiety levels, and craving score. The scores of each parameter were compared in three phases:  before intervention; after three months of intervention; and six months after the end of the study.
Results: Depression, anxiety, and craving scores decreased six months after the end of the previous study. This decrease was significant in the craving score (P = 0.011). No significant increase was observed in the frequency of use. The regression analysis showed a negative relationship between craving and the progression of phases.
Conclusion: The Deaddicta product may have desirable and effective properties in decreasing temptation and, as a result, the maintenance treatment of opioid dependence.

Keywords: Craving, Datura Stramonium L, Opium dependence, Persian Medicine.
Full-Text [PDF 753 kb]   (143 Downloads)    
Type of Study: Original Article | Subject: pharmacology
Received: 2023/04/10 | Accepted: 2024/02/24 | Published: 2024/02/24
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moosavyzadeh A, Ghaffari F, Mohammad Bagher Saberi zafarghandi M B, Talafi Noghani M, Hassanpour H, Emadi F, et al . Deaddicta® for maintenance treatment of Opioid-dependence: A six-month follow-up. Caspian J Intern Med 2024; 15 (2) :318-327
URL: http://caspjim.com/article-1-3910-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 15, Issue 2 (Spring 2024) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 40 queries by YEKTAWEB 4645